07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

New England Biolabs, Roche enabling technology news

The Australian Patent Office ruled that claims in Roche's Patent No. 632,857 covering naturally-occurring DNA polymerases from Thermus bacteria species are invalid. The technology is used in polymerase chain reaction (PCR). Biolabs and Bresagen Ltd....
08:00 , Dec 18, 2006 |  BC Week In Review  |  Company News

BresaGen, Hospira deal

HSP completed its previously announced acquisition of BGN for A$0.14 per share in cash, or about A$21 million (US$16.1 million) (see BioCentury, Aug. 21). BresaGen Ltd. (ASX:BGN; BSGNY), Adelaide, Australia   Hospira Inc. (HSP), Lake...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Company News

BresaGen board of directors update

BresaGen Ltd. (ASX:BGN; BSGNY), Thebarton, Australia   Business: Biomanufacturing, Veterinary   Appointed: Mark Baker, country manager of Australia at Hospira Inc.; and Thomas Werner, SVP of finance and CFO of Hospira   Resigned: Stephen Jones,...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Company News

BresaGen, Hospira deal

HSP proposed to acquire biomanufacturing company BGN for A$0.14 per share in cash, or about A$21 million (US$16.1 million) based on BGN's 149.9 million shares outstanding. The deal price is a 40% premium to BGN's...
00:35 , Aug 15, 2006 |  BC Extra  |  Company News

Hospira to buy BresaGen

On Friday, Hospira (HSP) proposed to acquire biomanufacturing company BresaGen (ASX:BGN; BSGNY) for A$0.14 per share in cash, or about A$21 million (US$16.1 million) based on BGN's 149.9 million shares outstanding. The deal price is...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

BresaGen, Domantis deal

BGN will use its protEcol Services technology to examine the feasibility of producing Domantis' domain antibodies (dAbs) in E. coli. BresaGen Ltd. (ASX:BGN; BSGNY), Adelaide, Australia   Domantis Ltd. , Waltham, Mass.   Business: Supply/Service...
07:00 , Aug 8, 2005 |  BC Week In Review  |  Company News

BresaGen, Opsona deal

BGN will use its protEcol Services technology to conduct feasibility studies and process development for the planned large-scale cGMP manufacture of Opsona's recombinant OPN-201 in E. coli. The im-munomodulator is in preclinical development for an...
07:00 , Aug 8, 2005 |  BC Week In Review  |  Company News

BresaGen, Pepgen deal

BGN's protEcol Services business unit will further develop an E. coli-based process to produce Pepgen's Neoferon interferon alpha analog and produce GLP recombinant protein. The process was developed under a 2004 deal. BresaGen Ltd. (ASX:BGN;...
08:00 , Jan 26, 2004 |  BC Week In Review  |  Company News

BresaGen agbio/environmental, autoimmune, cancer news

BGN appointed Ferrier Hodgson as administrators. The appointment follows the termination of negotiations with CM Capital Investments, which was considering investing in BGN. BGN also temporarily suspended its trading on the Australian Stock Exchange. BresaGen...
08:00 , Jan 26, 2004 |  BC Week In Review  |  Company News

BresaGen board of directors update

BresaGen Ltd. (ASX:BGN; BSGNY), Adelaide, Australia   Business: Agbio/Environmental, Autoimmune, Cancer   Appointed: Rudy Mazzocchi as chairman   Resigned: Peter Hart; Chris Juttner; and John Harkness  ...